Zhitong Finance App News, Shisi Pharmaceutical Group (02005.HK) issued an announcement. The Group has obtained approval from the China National Drug Administration for the production of phenobibrate choline sustained-release capsules (135mg), which is a Class 4 chemical drug, which is deemed to have passed the consistency evaluation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.